Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Elise Cai, MD, PhD

Title(s)Hematology/Oncology Fellow, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    California Institute of TechnologyBS2013Biology
    University of WashingtonPhD2019Molecular and Cellular Biology
    University of WashingtonMD2021Medicine
    UCSFResidency2024Internal Medicine
    UCSFFellowship2027Hematology/Oncology

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Integrated clinical and molecular characterization of WNT pathway alterations in metastatic castration-resistant prostate cancer (mCRPC) liver metastases (mets). Journal of Clinical Oncology. 2026; 44(16_suppl):5048. Cai EY, Zhang L, Shakhnazaryan N, Ding CK, Foye A, Small EJ, Quigley D, Aggarwal RR, Zhu X. View Publication.
    2. Clinical and genomic predictors of outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis. Journal of Clinical Oncology. 2026; 44(16_suppl):4560. Cai EY, Zhang L, Reyes KR, Thomas Z, Jiang CY, Oh E, Jindal T, Zhong JY, Casas SJ, Fahey C, Gupta S, Shah S, Basu A, Grivas P, Tripathi A, Brown JR, Alhalabi O, Tsung I, Campbell MT, Koshkin VS. View Publication.
    3. A phase 1b/2 study of FOR46 in combination with enzalutamide (enza) in patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2026; 44(7_suppl):149. Cai EY, Zhang L, Robinson W, Avins D, de Kouchkovsky I, Kwon D, Desai A, Fitzgerald KN, Bose R, Chou J, Friedlander TW, Koshkin VS, Zhu X, Younger N, Aslam M, Gonzales G, Small EJ, Liu B, Flavell RR, Aggarwal RR. View Publication.
    4. Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis. Journal of Clinical Oncology. 2026; 44(7_suppl):668. Cai EY, Zhang L, Reyes KR, Thomas Z, Jiang CY, Oh E, Jindal T, Zhong J, Jaime-Casas S, Fahey C, Gupta S, Shah S, Basu A, Grivas P, Tripathi A, Brown J, Alhalabi O, Tsung I, Campbell M, Koshkin VS. View Publication.
    5. Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP). Journal of Clinical Oncology. 2026; 44(7_suppl):800. Jindal T, Cai EY, Reyes KR, Jiang CY, Thomas Z, Jang A, Zhong JY, Alhalabi O, Campbell MT, Koshkin VS, Brown JR. View Publication.
    6. Impact of HER2 expression and ERBB2 alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis. Journal of Clinical Oncology. 2026; 44(7_suppl):794. Reyes KR, Zhang L, Cai EY, Thomas Z, Jiang CY, Oh E, Jindal T, Zhong JY, Jaime-Casas S, Milowsky MI, Nizam A, Shah S, Basu A, Grivas P, Tripathi A, Brown JR, Alhalabi O, Tsung I, Campbell MT, Koshkin VS. View Publication.
    7. Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC). Journal of Clinical Oncology. 2026; 44(7_suppl):704. Jindal T, Jiang CY, Cai EY, Zhong JY, Oh E, Jaime-Casas S, Bakaloudi D, Emamekhoo H, Zakharia Y, Nizam A, Milowsky MI, Shah S, Basu A, Grivas P, Tripathi A, Tsung I, Brown JR, Alhalabi O, Koshkin VS. View Publication.
    8. Association of HER2 and NECTIN4 expression with clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP). Journal of Clinical Oncology. 2026; 44(7_suppl):796. Reyes KR, Shipp CA, Ding C, Chan E, Zhu X, Cai EY, Fitzgerald KN, Desai A, Hsu SC, de Kouchkovsky I, Younger NS, Kwon DH, Aggarwal RR, Seyedin SN, Porten SP, Chou J, Friedlander TW, Chu CE, Koshkin VS. View Publication.
    9. Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. Journal of Clinical Oncology. 2026; 44(7_suppl):705. Jiang CY, Hwang H, Thomas Z, Jindal T, Cai EY, Jang A, Oh E, Bakaloudi DR, Tripathi A, Shah S, Gupta S, Grivas P, Tsung I, Brown JR, Koshkin VS, Campbell MT, Alhalabi O. View Publication.
    10. Factors associated with inferior outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with first-line enfortumab vedotin plus pembrolizumab (1L EV+P): results from UNITE. European Urology. 2026; 89:S1-2. Nizam A, Jindal T, Cai EY, Jiang CY, Thomas Z, Oh E, Nguyen CB, Jang A, Zhong J, Reyes K, Jaime-Casas S, Bakaloudi DR, Khaki AR, Govindarajan A, Gupta S, Shah SA, Milowsky MI, Grivas P, Tripathi A, Brown JR, Tsung I, Campbell MT, Alhalabi O, Koshkin VS. View Publication.
    11. Outcomes of autologous transplant, allogeneic transplant, and CAR T cell therapy in TP53 altered mantle cell lymphoma: a multi-institution retrospective analysis. Hematological Oncology. 2023; 41(S2):156-158. Messmer M, Stack A, Deng M, Handorf E, Kapoor N, Sawalha Y, Bock AM, Wang Y, Graf K, Greenwell B, Cleveland J, Advani R, Adrianzen Herrera D, Cai EY, Spinner M, Hassan A, Rajguru S, Phillips MS, Smith SD, Brooks T, Bond D, Hill B, Murphy J, Wagner-Johnston N, Zahid M, Awan FT, Ramakrishnan Geethakumari P, Tompkins W, Deshpande S, Svoboda J, Ryu C, Amengual J, Anna J, Kamdar M, Goparaju K, Martin J, Burkart M, Karmali R, Khan A, Modi D, Nickel M, Hambley B, Baron K, Shah H, Wallace D, Friedberg JW, Hannah C, Bachanova V, Ghosh N, Park S, David K, Darrah J, Fisher RI, Khan N. View Publication.
    12. A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. Sci Rep. 2021 02 25; 11(1):4609. Cai EY, Garcia J, Liu Y, Vakar-Lopez F, Arora S, Nguyen HM, Lakely B, Brown L, Wong A, Montgomery B, Lee JK, Corey E, Wright JL, Hsieh AC, Lam HM. PMID: 33633154; PMCID: PMC7907272.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    13. Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress. Cell Stem Cell. 2020 Aug 06; 27(2):270-283.e7. Cai EY, Kufeld MN, Schuster S, Arora S, Larkin M, Germanos AA, Hsieh AC, Beronja S. PMID: 32516567; PMCID: PMC7993921.
      View in: PubMed   Mentions:
    14. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Sci Transl Med. 2019 Jul 31; 11(503). Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. PMID: 31366581; PMCID: PMC6746573.
      View in: PubMed   Mentions:
    Elise's Networks
    Concepts (27)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-23-g6a590cb1 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.